logo

ALT

Altimmune
--
--(--)
Market Open: --
--
--(--)
Post-Market: --

ALT Profile

Altimmune, Inc.

A company that develops medical products to stimulate robust and durable immune responses for the prevention

Biological Technology
04/25/2005
05/05/2017
NASDAQ Stock Exchange
59
12-31
Common stock
910 Clopper Road, Suite 201S, Gaithersburg, MD 20878
--
Altimmune, Inc., was incorporated under the laws of the State of Delaware on April 25, 2005. The company is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver disease. The Company's lead product candidate, pemvidutide (formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (" MASH "), formerly known as non-alcoholic steatohepatitis (" NASH ").